Citadel Advisors’s Theriva Biologics TOVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-36,018
| Closed | -$15.6K | – | 14127 |
|
|
2025
Q2 | $15.6K | Buy |
+36,018
| New | +$29.2K | ﹤0.01% | 12153 |
|
|
2024
Q2 | – | Sell |
-987
| Closed | -$11.6K | – | 15413 |
|
|
2024
Q1 | $11.6K | Sell |
987
-1,331
| -57% | -$15.6K | ﹤0.01% | 13402 |
|
|
2023
Q4 | $24.9K | Buy |
+2,318
| New | +$28.5K | ﹤0.01% | 12435 |
|
|
2023
Q2 | – | Sell |
-824
| Closed | -$14.4K | – | 15250 |
|
|
2023
Q1 | $14.4K | Buy |
+824
| New | +$17.1K | ﹤0.01% | 13315 |
|
|
2022
Q4 | – | Sell |
-2,243
| Closed | -$55K | – | 15461 |
|
|
2022
Q3 | $55K | Buy |
+2,243
| New | +$86.1K | ﹤0.01% | 11559 |
|
|
2022
Q1 | – | Sell |
-1,112
| Closed | -$76K | – | 14583 |
|
|
2021
Q4 | $76K | Buy |
1,112
+937
| +535% | +$88.4K | ﹤0.01% | 12981 |
|
|
2021
Q3 | $20K | Buy |
175
+133
| +317% | +$16.5K | ﹤0.01% | 13640 |
|
|
2021
Q2 | $6K | Sell |
42
-2,114
| -98% | -$303K | ﹤0.01% | 13565 |
|
|
2021
Q1 | $368K | Buy |
+2,156
| New | +$426K | ﹤0.01% | 10373 |
|
|
2019
Q2 | – | Sell |
-102
| Closed | -$17K | – | 9857 |
|
|
2019
Q1 | $17K | Buy |
102
+47
| +85% | +$7.79K | ﹤0.01% | 9094 |
|
|
2018
Q4 | $8K | Buy |
+55
| New | +$13.1K | ﹤0.01% | 8957 |
|
|
2018
Q3 | – | Sell |
-13
| Closed | -$28K | – | 9692 |
|
|
2018
Q2 | $28K | Buy |
+13
| New | +$29.8K | ﹤0.01% | 8579 |
|
|
2018
Q1 | – | Sell |
-28
| Closed | -$122K | – | 8788 |
|
|
2017
Q4 | $122K | Buy |
28
+21
| +300% | +$131K | ﹤0.01% | 7358 |
|
|
2017
Q3 | $55K | Buy |
+7
| New | +$40.5K | ﹤0.01% | 7162 |
|
|
2016
Q3 | – | Sell |
-2
| Closed | -$39K | – | 7776 |
|
|
2016
Q2 | $39K | Hold |
2
| – | – | ﹤0.01% | 6458 |
|
|
2016
Q1 | $32K | Buy |
+2
| New | +$30.1K | ﹤0.01% | 6362 |
|
|
2015
Q4 | – | Sell |
-5
| Closed | -$95K | – | 9201 |
|
|
2015
Q3 | $95K | Sell |
5
-5
| -50% | -$123K | ﹤0.01% | 7002 |
|
|
2015
Q2 | $243K | Buy |
+10
| New | +$201K | ﹤0.01% | 6056 |
|
|
2015
Q1 | – | Hold |
0
| – | -$1K | – | 8848 |
|
|
2014
Q4 | – | Sell |
-2
| Closed | -$26.9K | – | 8422 |
|
|
2014
Q3 | $28K | Hold |
2
| – | – | ﹤0.01% | 7256 |
|
|
2014
Q2 | $33K | Sell |
2
-3
| -60% | -$47.6K | ﹤0.01% | 7032 |
|
|
2014
Q1 | $105K | Buy |
+5
| New | +$103K | ﹤0.01% | 6151 |
|
Other funds holding TOVX
IC
VF
BFM
XT
Citadel Advisors's TOVX Position: Q3 2025 in Review
Citadel Advisors sold out of Theriva Biologics (TOVX) in Q3 2025, closing a stake of 36,018 shares — an estimated $15.6K sold.
Citadel Advisors first reported a position in TOVX in Q1 2014 and held it in 21 quarters. The position peaked at $368K in Q1 2021. 20 funds tracked by Wall St. Rank hold TOVX as of Q3 2025.
- Citadel Advisors reported no remaining Theriva Biologics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 36,018 Theriva Biologics shares in Q3 2025, an estimated $15.6K.
- Citadel Advisors first reported a position in Theriva Biologics in Q1 2014 and held it in 21 quarters.
- Citadel Advisors's Theriva Biologics position peaked at $368K in Q1 2021.
- 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.